NDTV Profit’s special research section collates quality and in-depth equity and economy research reports from across India’s top brokerages, asset managers and research agencies. These reports offer NDTV Profit’s subscribers an opportunity to expand their understanding of companies, sectors and the economy.
Deven Choksey Research Report
Sai Life Sciences Ltd. will launch its initial public offering on December 11 and the offer closes for subscription on Dec. 13. The globally recognized CRDMO has fixed the price band in the range of Rs 522–549 per share. The minimum order lot is minimun 27 shares.
The Rs 3,042.62 IPO comprises of a fresh issue worth Rs 950 crore and an offer for sale of Rs 2,092.62 crore.
The shares will be listed on the exchanges on Dec. 18.
Object of the offer
Repayment/ prepayment of certain outstanding borrowings.
General Corporate Purpose.
Outlook and Valuation:
Sai Life Sciences is a globally recognized Contract Research, Development, and Manufacturing Organization offering integrated services across drug discovery, development and manufacturing, with a strong presence in regulated markets like the US, UK and Europe.
The company benefits from a robust product pipeline, serving over 280 clients, including 18 of the top 25 global pharmaceutical firms. However, its significant reliance on key clients, limited diversification across treatment areas and high infrastructure costs pose risks to sustained profitability.
With a P/E multiple of 138x, the valuation appears stretched compared to peers in the industry. This premium valuation, coupled with operational risks and margin pressures, limits its investment attractiveness despite growth potential in the global CRDMO market. Therefore, we assign an “Avoid” rating.
Click on the attachment to read the full report:
DISCLAIMER
This report is authored by an external party. NDTV Profit does not vouch for the accuracy of its contents nor is responsible for them in any way. The contents of this section do not constitute investment advice. For that you must always consult an expert based on your individual needs. The views expressed in the report are that of the author entity and do not represent the views of NDTV Profit.
Users have no license to copy, modify, or distribute the content without permission of the Original Owner.
As a Subscriber you get
Stories
RECOMMENDED FOR YOU
Sai Life Sciences Block Deal: Domestic Mutual Funds Buy In Led By Nippon India
Jun 20, 2025
Sai Life, Northern Arc, PFC, REC, Globus Spirits, Galaxy Surfactants and Hubtown Are Buzzing On Dealer Desk
Jun 20, 2025
Sai Life Sciences Block Deal: TPG Offers To Sell 6% Stake For Rs 888 Crore
Jun 19, 2025
Vishal Mega Mart, Sai Life Sciences: Shares Worth Rs 39,000 Crore To Exit Lock-Ins On Tuesday
Jun 16, 2025
POPULAR